International conference on gamma delta T cells and their role in cancer treatment
Official title: 11th International gamma delta T Cell Conference
Funded at Duke University · NIH-11072797 · Data updated 2026-11-12
This conference is bringing together scientists and doctors to talk about special immune cells called gamma delta T cells, which play an important role in fighting diseases like cancer and autoimmune disorders, and they'll be sharing new ideas on how to use these cells for better treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | November 12, 2024 |
| Project end | October 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $5,300 |
| NIH project number | 1R13AI188918-01 |
| Project ID | NIH-11072797 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include patients with cancer or autoimmune diseases who may be eligible for new therapies developed from gamma delta T cell research.
✕Less likely to help
Patients who are not affected by cancer or autoimmune diseases may not receive direct benefits from this research.
What this research studies
The 11th International gamma delta T Cell Conference will gather researchers and clinicians to discuss the development and function of gamma delta T lymphocytes, which are crucial for adaptive immunity. This conference will focus on how these cells can be harnessed for innovative cell-based therapies, particularly in the context of cancer treatment and autoimmune diseases. Attendees will have the opportunity to share unpublished research findings, engage in discussions, and network with leaders in the field, fostering collaboration and new ideas for future studies.
Why it matters
Potential benefit: If successful, this research could lead to advancements in cancer immunotherapy and improved treatment options for patients with autoimmune conditions.
How similar studies have gone: Previous conferences on similar topics have successfully fostered collaboration and innovation in the field of immunotherapy, indicating a strong potential for impactful outcomes.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Ciofani, Maria — Duke University
- Study coordinator: Ciofani, Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.